Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6011 Dose Response in RA
NCT02960438Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2016
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of quetmolimab in rheumatoid arthritis (RA), sponsored by Eisai Co., Ltd. Primary endpoint: American College of Rheumatology 20 Response at 12 weeks. Started Oct 2016; status: completed.
02
Drugs
quetmolimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02960438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960438.